Okay. Let’s not get our hopes up TOO much but I’ve come across an agenda for the NICE Technology Appraisal Committee meeting on Tuesday 15 January 2013. Listed as point 6 on the agenda is:

6. Rapid review of TA251 – dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70)

This would indicate to me that something has changed, perhaps BMS have offered a Patient Access Scheme (discounted price) for dasatinib and that NICE are duty bound to review the guidance. This is NOT a formality but there is a chance that the guidance could change. It would be wonderful to think we all had a small part to play in this, but the big thanks has to go to Leukaemia Care and the group of charities who have supported and worked with them – their unwavering pressure has been vital…so far.

If I hear anything else then I will post here, but let’s keep the pressure up and keep our fingers crossed.

Original link here: http://www.nice.org.uk/newsroom/publicmeetings/TAC15January2013.jsp